Literature DB >> 19083245

A potentially deleterious new CYP2C9 polymorphism identified in an African American patient with major hemorrhage on warfarin therapy.

J A Goldstein, J A Blaisdell, N A Limdi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19083245      PMCID： PMC2662477          DOI： 10.1016/j.bcmd.2008.10.011

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN： 1079-9796            Impact factor:   3.039


× No keyword cloud information.
  13 in total

1.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences.

Authors:  O Gotoh
Journal:  J Biol Chem       Date:  1992-01-05       Impact factor: 5.157

2.  Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Authors:  Nita A Limdi; Donna K Arnett; Joyce A Goldstein; T Mark Beasley; Gerald McGwin; Brian K Adler; Ronald T Acton
Journal:  Pharmacogenomics       Date:  2008-05       Impact factor: 2.533

3.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Authors:  T H Sullivan-Klose; B I Ghanayem; D A Bell; Z Y Zhang; L S Kaminsky; G M Shenfield; J O Miners; D J Birkett; J A Goldstein
Journal:  Pharmacogenetics       Date:  1996-08

4.  Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.

Authors:  J Imai; I Ieiri; K Mamiya; S Miyahara; H Furuumi; E Nanba; M Yamane; Y Fukumaki; H Ninomiya; N Tashiro; K Otsubo; S Higuchi
Journal:  Pharmacogenetics       Date:  2000-02

5.  Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.

Authors:  R S Kidd; T B Curry; S Gallagher; T Edeki; J Blaisdell; J A Goldstein
Journal:  Pharmacogenetics       Date:  2001-12

6.  Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies.

Authors:  M Shintani; I Ieiri; K Inoue; K Mamiya; H Ninomiya; N Tashiro; S Higuchi; K Otsubo
Journal:  Clin Pharmacol Ther       Date:  2001-08       Impact factor: 6.875

7.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Authors:  Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

8.  Crystal structure of human cytochrome P450 2C9 with bound warfarin.

Authors:  Pamela A Williams; Jose Cosme; Alison Ward; Hayley C Angove; Dijana Matak Vinković; Harren Jhoti
Journal:  Nature       Date:  2003-07-13       Impact factor: 49.962

9.  Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Authors:  N A Limdi; G McGwin; J A Goldstein; T M Beasley; D K Arnett; B K Adler; M F Baird; R T Acton
Journal:  Clin Pharmacol Ther       Date:  2007-07-25       Impact factor: 6.875

10.  Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans.

Authors:  Na Limdi; Ja Goldstein; Ja Blaisdell; Tm Beasley; Ca Rivers; Rt Acton
Journal:  Per Med       Date:  2007-05-01       Impact factor: 2.512
View more
  4 in total

1.  Management of warfarin in children with heart disease.

Authors:  William T Mahle; Scott A Simpson; Paulette Fye; Michael E McConnell
Journal:  Pediatr Cardiol       Date:  2011-04-17       Impact factor: 1.655

Review 2.  Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.

Authors:  Frank S Ong; Joshua L Deignan; Jane Z Kuo; Kenneth E Bernstein; Jerome I Rotter; Wayne W Grody; Kingshuk Das
Journal:  Pharmacogenomics       Date:  2012-03       Impact factor: 2.533

3.  Search for the molecular basis of ultra-rapid CYP2C9-catalysed metabolism: relationship between SNP IVS8-109A>T and the losartan metabolism phenotype in Swedes.

Authors:  Fazleen H M Hatta; Lay Kek Teh; Anders Helldén; Karin Engström Hellgren; Hyung-Keun Roh; Mohd Zaki Salleh; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2012-02-01       Impact factor: 2.953

4.  Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients.

Authors:  Nassr Eldin M A Shrif; Hong-Hee Won; Seung-Tae Lee; Jun-Hee Park; Ka-Kyung Kim; Min-Ji Kim; Seonwoo Kim; Soo-Youn Lee; Chang-Seok Ki; Ihsan M Osman; Enaam A Rhman; Ibtisam A Ali; M N A Idris; Jong-Won Kim
Journal:  Eur J Clin Pharmacol       Date:  2011-05-18       Impact factor: 2.953
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.